These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12727048)

  • 1. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.
    Passik SD; Kirsh KL; Theobald DE; Dickerson P; Trowbridge R; Gray D; Beaver M; Comparet J; Brown J
    J Pain Symptom Manage; 2003 May; 25(5):485-8. PubMed ID: 12727048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
    Passik SD; Navari RM; Jung SH; Nagy C; Vinson J; Kirsh KL; Loehrer P
    Cancer Invest; 2004; 22(3):383-8. PubMed ID: 15493359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
    Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
    Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
    Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
    Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
    Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
    Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
    Yanai T; Iwasa S; Hashimoto H; Ohyanagi F; Takiguchi T; Takeda K; Nakao M; Sakai H; Nakayama T; Minato K; Arai T; Suzuki K; Shimada Y; Nagashima K; Terakado H; Yamamoto N
    Int J Clin Oncol; 2018 Apr; 23(2):382-388. PubMed ID: 29039073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: a pilot study with ACTH-Depot plus tropisetron.
    Santini D; Vincenzi B; Fossati C; D'Angelillo RM; Patti G; Bianco V; Avvisati G; Tonini G
    Med Oncol; 2001; 18(2):131-5. PubMed ID: 11778758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
    Navari RM; Gray SE; Kerr AC
    J Support Oncol; 2011; 9(5):188-95. PubMed ID: 22024310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
    Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting.
    Chanthawong S; Subongkot S; Sookprasert A
    J Med Assoc Thai; 2014 Mar; 97(3):349-55. PubMed ID: 25123016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.
    Fonte C; Fatigoni S; Roila F
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):214-21. PubMed ID: 25779971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
    Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
    Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
    Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
    Wang SY; Yang ZJ; Zhang L
    Asian Pac J Cancer Prev; 2014; 15(22):9587-92. PubMed ID: 25520071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.